Navigation Links
Lymphoblastic in Medical News

New genes involved in acute lymphoblastic leukemia play fundamental role in prognosis of the disease

This release is available in Spanish . The inactivity or "silence" of certain genes plays a fundamental role in the prognosis of acute lymphoblastic leukemia as well as in response to treatment, according to the results of research involving a team made up of specialists from the Universi...

Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia

BETHESDA, Md., Oct. 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for the treatment of cancer, inflammatory and autoimmune diseases, announced today that the Paul-Ehrlich Insti...

A New Treatment Discovered For Acute Lymphoblastic Leukemia

A study undertaken by a group of Spanish scientists, amongst which were members of the University Clinic of the University of Navarra and the Centre for Applied Medical Research// (CIMA) of the same university has recently discovered a new line of treatment for patients with acute lymphoblastic leu...

'Good' And 'Evil' Clones Of Acute Lymphoblastic Leukaemia cells

According to Australian scientists, there are two types of acute lymphoblastic leukaemia (ALL) cells, good and bad. //The latter type of cells are those that have a pre-existing immunity to drugs used to treat ALL, that is responsible for relapse after treatment. The discovery means that now re...

Acute Lymphoblastic Leukemia May Attain a 90% Cure Rate

The improvements made in diagnoses and treatment of the fatal childhood cancer acute lymphoblastic leukemia (ALL) will result in a cure rate of 90%, according to researchers belonging to the St. Jude Children's Research Hospital.// The progressive improvement in the cure rate since 1962, whe...

Gene Fusion Test to screen children’s with Acute Lymphoblastic Leukemi

Dr Moorman and his colleagues from Southampton University have found a new gene based test for identifying DNA fusion, in which DNA of two or more genes fuse. The research team is focusing on detection of genes // linked to the most common form of childhood leukemia, which is called as Acute Lympho...

Micromet, Inc. Reports Second Quarter 2009 Financial Results

...presentation of blinatumomab phase 2 data in acute lymphoblastic leukemia (ALL) at the 14(th) Congress of the Europ...ook forward to initiating a pivotal trial in acute lymphoblastic leukemia in 2010," stated Christian Itin, Ph.D., P...cal trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial fo...

DEET in Bug Spray Tied to Neural Damage in Mice

...ween exposure to acetylcholinesterase inhibitors and the Gulf War illness suffered by many veterans. Organophosphates have also been linked with acute lymphoblastic leukemia, the most common form of leukemia in children. More information The U.S. Environmental Protection Agency has more on DEET. ...

Common household pesticides linked to childhood cancer cases in Washington area

...chers at the Georgetown's Lombardi Comprehensive Cancer Center finds a higher level of common household pesticides in the urine of children with acute lymphoblastic leukemia (ALL), a cancer that develops most commonly between three and seven years of age. The findings are published in the August issue of the jour...

Comprehensive Look at Rare Leukemia Finds Relatively Few Genetic Changes Launch Disease

... mutations involve a single chemical change in the molecular building blocks of DNA. The data demonstrated that, in contrast to pediatric acute lymphoblastic leukemia (ALL), AML is characterized by a very low burden of mutations. The researchers found slightly more than two CNAs per AML patient, and less th...
Lymphoblastic in Medical Technology

Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation

St. Jude study shows personalized chemotherapy can improve cure rate and avoid the use of radiation in acute lymphoblastic leukemia treatment MEMPHIS, Tenn., June 24 /PRNewswire-USNewswire/ -- Childhood acute lymphoblastic leukemia (ALL) can be successfully treated using a carefully person...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

German Multicenter ALL Study Group Presented Data at the 14th Congress of the European Hematology Association Showing High Response Rate in Patients with Minimal Residual Disease BERLIN, June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing ...

Expert Insights in Acute Lymphoblastic Leukemia: Current Challenges and Future Directions

Complimentary Continuing Education Online Activity and Podcast for Nurses and Pharmacists VOORHEES, N.J., April 22 /PRNewswire/ -- Acute lymphoblastic leukemia (ALL) is a complex heterogeneous disease which, despite significant advances in the treatment of pediatric patients, is often fatal i...

Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia

- 31% COMPLETE RESPONSE RATE - MEDIAN SURVIVAL OF 10.5 MONTHS IN COMPLETE RESPONDERS - FINAL DATA TARGETED FOR 2009 ASH ANNUAL MEETING SOUTH SAN FRANCISCO, Calif., March 3 /PRNewswire-FirstCall/ -- Hana Biosciences (Nasdaq: HNAB ) today announced new positive preliminary efficacy ...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia

DUBLIN, Calif., Dec. 8 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that its oral PIM kinase inhibitor, SGI-1776, is effective both in vitro and in vivo in preclinical mode...

Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia

BETHESDA and GAITHERSBURG, Md., June 12 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ) and MedImmune announced today that the first patient has started treatment in a multi-center, phase 2 trial conducted in Germany investigating BiTE(R) antibody blinatumomab (MT103/MEDI-538) in pat...

St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia

A new study shows that loss of Arf gene in presence of BCR-ABL mutation leaves ALL cells vulnerable to the growth-enhancing environment of the bone marrow, helping cells develop immunity to the anti-leukemia drug imatinib MEMPHIS, Tenn., Aug. 29 /PRNewswire-USNewswire/ -- Results of a study ...

Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia

- Results from a Children's Oncology Group (COG) Study Presented at American Society of Clinical Oncology Annual Meeting - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

...odies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in ...

Mutant Genes in High-Risk Childhood Leukemias Identified

...EMPHIS, Tenn., May 19 /PRNewswire-USNewswire/ -- A research team has pinpointed a new class of gene mutations, which identify cases of childhood acute lymphoblastic leukemia (ALL) that have a high risk of relapse and death. The finding suggests specific drugs that could treat this high-risk leukemia subtype in chi...
Lymphoblastic in Medical Dictionary

Acute lymphoblastic

Acute lymphoblastic leukemia (ALL), is a form of leukemia, or cancer of the white blood cells characterized by excess lymphoblasts. Expert-reviewed information summary about the treatment of childhood acute lymphoblastic leukemia. ... Childhood acute lymphoblastic leukemia (AL...

Acute lymphocytic leukemia

... Acute lymphoblastic leukemia (ALL), is a form of leukemia , or can...ia, the cancer of the blood or ... 4.1 Acute lymphoblastic leukemia (ALL) 4.2 Chronic lymphocytic leukem...ute lymphocytic leukemia (also called acute lymphoblastic leukemia or ALL) is uncommon among adults, but i...
Lymphoblastic in Biological News

St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia

Results of a study by investigators at St. Jude Childrens Research Hospital provide strong evidence for why the targeted therapy drug, imatinib, or Gleevec, which has revolutionized the treatment of chronic myelogenous leukemia, (CML) is often unable to prevent relapse of a particularly aggressive...

Comprehensive look at rare leukemia finds relatively few genetic changes launch disease

...oint mutations involve a single chemical change in the molecular building blocks of DNA. The data demonstrated that, in contrast to pediatric acute lymphoblastic leukemia (ALL), AML is characterized by a very low burden of mutations. The researchers found slightly more than two CNAs per AML patient, and less th...

St. Jude identifies genomic causes of a certain type of leukemia relapse

... Scientists at St. Jude Children's Research Hospital have identified distinctive genetic changes in the cancer cells of children with acute lymphoblastic leukemia (ALL) that cause relapse. The finding offers a pathway to designing treatments for ALL relapse in children and, ultimately, in adults. The...

Lab study shows methadone breaks resistance in untreatable forms of leukemia

...ory culture because this cancer also expresses the opioid receptor. Theirs is the first study to look at use of the agent in leukemia, specifically in lymphoblastic leukemia T-cell lines and human myeloid leukemia cell lines. They found that methadone was as effective as standard chemotherapies and radiation tr...

Ireland Cancer Center researchers advance stem cell gene therapy

...cology Group (ECOG) presented data that show that Imatninib (Gleevec) does not change outcomes on patients with Philadelphia Chromosome Positive Acute lymphoblastic Leukemia. Dr. Lazarus presented an assessment of data over 30 years regarding acute leukemia and its management. He found that all avenues lea...

Daisies lead scientists down path to new leukemia drug

...the end of 2007. Investigators expect to initially enroll about a dozen adult volunteers whove been diagnosed with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or other types of blood or lymph cancers, Jordan said. Under development is dimethylamino-parthenolide (DMAPT), a form of parthenoli...

Research shows cord blood comparable to matched bone marrow

...d Blood Program at the New York Blood Center. The analysis included transplant outcomes in 785 children younger than 16 who had the diagnosis of acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). ...

Major gene study uncovers secrets of leukemia

...tigators at St. Jude Children's Research Hospital have discovered previously unsuspected mutations that contribute to the formation of pediatric acute lymphoblastic leukemia (ALL), the most common cancer in children. The discovery not only suggests novel methods for treating pediatric ALL, but also provides a road...

Knocking out survival protein could aid leukemia treatment

...n with several existing drugs might also offer an effective one-two punch against drug-resistant forms of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). The two forms of cancer kill about 20,500 Americans yearly. The survival protein is called Mcl1. It usually helps keep normal ce...

Leukemic cells find safe haven in bone marrow

... The cancer drug asparaginase fails to help cure some children with acute lymphoblastic leukemia (ALL) because molecules released by certain cells in the bone marrow counteract the effect of that drug, according to investigators at St. Ju...
Lymphoblastic in Biological Technology

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

BETHESDA, Md., Aug. 3 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it has received Orphan Drug Designation from the Europ...

Micromet Closes $80.5 Million Public Offering of Common Stock

...odies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in ...

Micromet Announces Pricing of Public Offering of Common Stock

...odies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in ...

Micromet Announces Public Offering of Common Stock

...odies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in ...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

...odies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in ...

Micromet Added to Russell 3000 Index

...odies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in ...

Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009

...odies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in ...

Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel

...odies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in ...

Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO

...cal trial with blinatumomab in patients with acute lymphoblastic leukemia (ALL) were chosen for an oral presentatio...l disease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing phase II stud...cal trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the trea...

Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009

... Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet's second BiTE antibody in clinical developme...
Lymphoblastic in Biological Products

MOLT - 4 cell line slides ( human: T lymphoblast; acute lymphoblastic leukemia ) from GeneTex

Description: Human MOLT-4 cells were cultured in RPMI 1640 with 2 mM L-glutamine and harvested at the log phase of growth. In order to keep the antigens in their native forms, cells were fixed in acetone-methanol. The cells are arrayed on a 12-well (5 mm) adhesive coated slide, with each wells surface specifi...
Company:GeneTex

Terminal deoxynucleotidyl transferase (TdT) Immunofluorescence Assay Kit from AbD Serotec

Description:...nor subpopulation of bone marrow prelymphocytes. Elevated levels of the enzyme and increased numbers of TdT cells are found to be associated with some lymphoblastic leukaemias and lymphomas. Presence of TdT thus provides a useful adjunct in the differentiation of leukaemias and also in monitoring response to thera...
Company:AbD Serotec
Other Tags
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, ... who was thought to be cured by immediate and aggressive ... of the AIDS-causing virus in her bloodstream, disappointed federal officials ... old, had remained virus-free even though she stopped taking HIV ... her remission would open the door to a functional cure ...
(Date:7/11/2014)... NY (PRWEB) July 11, 2014 ... ) investigation, Bernstein Liebhard LLP has been closely ... & Drug Administration’s (FDA) Obstetrics and Gynecology ... ways to mitigate the cancer risks associated with ... gynecological surgeries. According to a report published by ...
(Date:7/11/2014)... July 11, 2014 Datalogic brings a ... improving sanitation hospital wide. With their new Gryphon ... of disease, like the devastating MRSA, which claimed 5,500 ... GD4400-HC 2D and the Gryphon GM4400-HC 2D ... and can even read barcodes off of troublesome LCD ...
(Date:7/11/2014)... News) -- In people with sex addiction, pornography affects ... seen in drug addicts as they consume drugs, a ... brain activity between patients who have compulsive sexual behavior ... addicts," study author Dr. Valerie Voon, of the University ... release. Voon,s research involved 19 men with sex ...
(Date:7/11/2014)... 2014 Ticket Down is a reliable ... . When it comes to the summer concert schedule, it ... Georgia native is one of the biggest names in country music ... is currently out on his “That’s My Kind of Night” tour ... tour will be making through the rest of the summer and ...
Breaking Medicine News(10 mins):Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3
(Date:7/10/2014)... BELL, Pa. , July 2, 2014  Unisys Corporation,s ... Netherlands , Unisys Nederland N.V., today announced that it ... to deliver, implement and manage a new Basic Provision Biometrics ... Unisys won the contract with a solution ... identity management software. The term of the contract is up ...
(Date:7/10/2014)... DUBLIN , July 3, 2014 ... the addition of the "Global Gesture Recognition ... Market - Forecasts to 2020" report to ... Global Gesture Recognition & Touch-Less Sensing ... been around for a while, but the companies ...
(Date:7/10/2014)... , July 9, 2014  Acuity Market Intelligence today released ... 2014 Edition" indicating that the global market for National Electronic ... 2013 to 2018. During this time, the number of National ... 3.5 billion. Asia , with its vast ... National eID cards issued, while Europe ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2
Other Contents